Change over period: —
NSE · HESTERBIO
HESTER BISC
-7.7% from the 52-week high · +86.5% above the low
Hester Biosciences Ltd. is a holding company, which engages in the manufacture and trade of poultry vaccines and animal health products. The company is headquartered in Ahmedabad, Gujarat and currently employs 584 full-time employees. The firm is primarily engaged in the production and distribution of vaccines and health products. The company is also involved in the manufacturing of poultry vaccines and large animal vaccines and trading of poultry and large animal health products. Its segments include poultry healthcare and animal health care. The Company’s products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and WormPeril Tablets, WormPeril Puppy, Vitacoat, TumOnzym, Synoton, Petsglow, Pawfresh, Hestaliv, Hestaflam Tablet, Thermostable ND, and Hestacef DS.
The short version. HESTER BISC reported revenue of ₹98 crore for Sep 2026, up 38.0% from a year earlier. Net profit was ₹20 crore (up 42.9% year on year). Return on equity was 15.4% in Mar 2026. Promoter holding was 44.28% in Sep 2026, down 9.45 points over 8 quarters.
1 · The price
How has the stock traded?
HESTER BISC trades 7.7% below its 52-week high and 86.5% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹98 cr.
Sep 2026 net profit of ₹20 cr.
0.4 pts higher than a year earlier.
Revenue compounded at 6.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 98 | 77 | 100 | 77 | 71 | 84 | 82 | 63 |
| Net profit | 20 | 97 | 16 | 9 | 14 | 16 | 1 | 12 |
| Net margin % | 20.8 | 125.6 | 16.0 | 11.3 | 20.4 | 19.5 | 1.6 | 18.4 |
| EPS (₹) | 23.94 | 114.0 | 18.79 | 10.3 | 16.99 | 19.33 | 1.52 | 13.71 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 333 | 311 | 305 | 266 | 235 | 214 | 183 | 178 |
| Net profit | 56 | 27 | 19 | 27 | 39 | 34 | 29 | 42 |
| Net margin % | 16.7 | 8.8 | 6.2 | 10.0 | 16.7 | 16.1 | 15.9 | 23.3 |
| EPS (₹) | 65.41 | 32.31 | 22.2 | 31.3 | 46.22 | 40.47 | 34.29 | 48.86 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 15.4% in Mar 2026; debt to equity is 0.52.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 15.4 | 8.8 | 6.5 | 9.5 |
| Return on capital % | 15.3 | 9.1 | 8.5 | 8.6 |
| EBITDA margin % | 29.0 | 20.6 | 20.4 | 23.4 |
| Net margin % | 16.3 | 8.7 | 6.0 | 9.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 6.8% | 9.3% |
| Profit CAGR | 27.9% | 10.1% |
4 · The owners
Who holds it, and are they adding?
Down 9.45 pts over 8 quarters.
Down 0.28 pts over 8 quarters.
Up 0.06 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.73 | 53.73 | 53.73 | 53.73 | 53.73 | 53.73 | 53.73 | 44.28 | -9.45 |
| FII | 0.59 | 0.87 | 0.52 | 0.53 | 0.51 | 0.38 | 0.31 | 0.31 | -0.28 |
| DII | 0.02 | 0.02 | 0.02 | 0 | 0.01 | 0 | 0 | 0.08 | +0.06 |
| Public | 45.65 | 45.38 | 45.73 | 45.74 | 45.75 | 45.89 | 45.95 | 55.33 | +9.68 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Bandhan BSE Healthcare Index Fund0.06% of NAV
- Motilal Oswal BSE Healthcare ETF0.05% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for HESTER BISC are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about HESTER BISC
What is the HESTER BISC share price?
HESTER BISC (HESTERBIO) last closed at ₹2,352.10, up 0.17% on the day. Its 52-week range is ₹1,259.10 to ₹2,545.00.
What is the market cap of HESTER BISC?
HESTER BISC has a market capitalisation of about ₹1,985 crore. Its price-to-earnings ratio is 14.2.
How are HESTER BISC's latest results?
HESTER BISC reported revenue of ₹98 crore for Sep 2026, up 38.0% from a year earlier. Net profit was ₹20 crore (up 42.9% year on year). Return on equity was 15.4% in Mar 2026. Promoter holding was 44.28% in Sep 2026, down 9.45 points over 8 quarters.
Who owns HESTER BISC?
As of Sep 2026, shareholding was: Promoter 44.28%, FII 0.31%, DII 0.08%, Public 55.33%.
How many mutual funds hold HESTER BISC?
2 mutual fund schemes held HESTER BISC in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 06 Aug 2025 · Final Dividend - Rs. 7
- 22 Aug 2024 · Dividend - Rs. 6
- 13 Sep 2023 · Final Dividend - Rs. 8
- 11 Aug 2022 · Dividend - Rs. 10
- 05 Aug 2021 · Dividend - Rs. 10
- 27 Aug 2020 · Dividend - Rs. 6.6
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.